Early experience with resmetirom to treat metabolic dysfunction–associated steatohepatitis with fibrosis in a real-world setting
Our prescription pathway effectively dispensed resmetirom to nearly all patients who were prescribed resmetirom. One in 6 patients discontinued resmetirom, primarily due to side effects. This high discontinuation rate may be mitigated by modifying our follow-up from "prescribe and forget" to "prescribe and closely follow."
Authors
- Penelope G. Shackelford
- Neel Ravela
- Niharika R. Samala (ORCID: https://orcid.org/0000-0002-1993-5223)
- Lindsay Yoder (ORCID: https://orcid.org/0000-0002-6556-1162)
- Naga Chalasani (ORCID: https://orcid.org/0000-0003-2359-6030)
- Nadia Blessing
Institutions
- Indiana University Health (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1097/hc9.0000000000000670
- Citations
- 15
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 20.31